Current Report Filing (8-k)
April 22 2016 - 7:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
April 22, 2016
QLT Inc.
(Exact Name of Registrant as specified in its charter)
British Columbia, Canada
|
|
000-17082
|
|
N/A
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
887 Great Northern Way, Suite 250, Vancouver, B.C.
Canada, V5T 4T5
(Address of principal executive offices)
Registrants telephone number, including area code:
(604) 707-7000
Not Applicable
(Registrants name or former address, if change since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On April 22, 2016, QLT Inc. (the Company) issued a press release announcing that the Company has completed its enrollment in the Natural History Study in subjects with Inherited Retinal Disease phenotypically diagnosed with Retinitis Pigmentosa or Leber Congenital Amaurosis due to underlying Retinal Pigment Epithelial 65 protein or Lecithin:Retinol Acyltransferase gene mutations. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Number
|
|
Description
|
99.1
|
|
Press Release dated April 22, 2016
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
QLT INC.
|
|
|
|
By:
|
/s/
Glen Ibbott
|
|
Name:
|
Glen Ibbott
|
|
Title:
|
Senior Vice President, Finance and
Chief Financial Officer
|
|
Date: April 22, 2016
3
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024